Download PDF
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2020; 56(02): 102-111
DOI: 10.1055/s-0040-1714159
Review Article

Association of Comorbidities with Coronavirus Disease 2019: A Review

Abhilasha,
Prasenjit Mitra
1   Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
,
Smriti Suri
1   Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
,
Taru Goyal
1   Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
,
Radhieka Misra
2   Graduate Medical Scholar, Era’s Lucknow Medical College, and Hospital, Lucknow, India
,
Kuldeep Singh
2   Graduate Medical Scholar, Era’s Lucknow Medical College, and Hospital, Lucknow, India
,
M. K. Garg
3   Department of Medicine, All India Institute of Medical Sciences, Jodhpur, India
,
Sanjeev Misra
4   Department of Pediatrics, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
,
Praveen Sharma
1   Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

The novel Coronavirus disease 2019 (COVID-19) pandemic started with few cases of pneumonia of unknown origin in Wuhan, China. It has now become one of the significant public health emergencies of all time. Within 5 months of its existence, it has led to a significant impact on national and international policies. Apart from being a medical emergency, it is also affecting the global economy, and without proper measures, it may have severely impact the socioeconomic statuses of individuals. It has profoundly challenged the healthcare infrastructure, particularly in low- and middle-income nations. Every nation is trying to safeguard its population and the health workers as adequately as possible. While we still wait for the development of an absolute cure in the form of a vaccine, preventive measures have taken the lead in reducing the disease spread and breaking the chain of transmission. The knowledge gained from the clinical characteristics of patients has suggested markers or comorbid conditions that may aid in the risk assessment. This narrative review aims to provide an update on SARS-CoV-2, the causative virus of COVID-19, its pathogenesis, the clinical and laboratory features, and its association with several comorbid conditions that may influence the prognosis of this disease.

Keywords

COVID-19 - ACE2 - aging - diabetes - hypovitaminosis


Publication History

Article published online:
04 July 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 WHO. Coronavirus (COVID-19) events as they happen. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they- happen. Accessed May 17, 2020
  • 2 Hong KH, Lee SW, Kim TS. et al. Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea. Ann Lab Med 2020; 40 (05) 351-360
    CrossrefPubMedGoogle Scholar
  • 3 Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433
    CrossrefPubMedGoogle Scholar
  • 4 Chan JF-W, Kok K-H, Zhu Z. et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9 (01) 221-236
    Google Scholar
  • 5 Coronavirus Update (Live). 4,750,411 Cases and 313,805 Deaths from COVID-19 Virus Pandemic - Worldometer. Available at: https://www.worldometers.info/coronavirus/. Accessed May 17, 2020
  • 6 Mitra P, Misra S, Sharma P. COVID-19 pandemic in India: what lies ahead. Indian J Clin Biochem 2020; 1-3
    PubMedGoogle Scholar
  • 7 Perlman S. Another decade, another Coronavirus. N Engl J Med 2020; 382 (08) 760-762
    CrossrefPubMedGoogle Scholar
  • 8 Letko M, Munster V. Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV. Published online January 2020. DOI: 10.1101/2020.01.22.915660.
    CrossrefGoogle Scholar
  • 9 Dong N, Yang X, Ye L. et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-NCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. Microbiology 2020; DOI: 10.1101/2020.01.20.913368.
    CrossrefPubMedGoogle Scholar
  • 10 Zhou P, Yang X-L, Wang X-G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579 (7798) 270-273
    Google Scholar
  • 11 Yadav T, Saxena SK. Transmission cycle of SARS-CoV and SARS-CoV-2. In: Medical Virology: From Pathogenesis to Disease Control. Singapore: Springer; 2020: 33-42
    Google Scholar
  • 12 Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during Pregnancy and Possible Vertical Transmission. Am J Perinatol 2020; DOI: 10.1055/s-0040-1710050.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Jia HP, Look DC, Shi L. et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol 2005; 79 (23) 14614-14621
    CrossrefPubMedGoogle Scholar
  • 14 Zhang B, Zhou X, Qiu Y. et al. Clinical characteristics of 82 death cases with COVID-19. Infectious Diseases (Except HIV AIDS (Auckl) 2020; DOI: 10.1101/2020.02.26.20028191.
    CrossrefPubMedGoogle Scholar
  • 15 Xia S, Zhu Y, Liu M. et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol 2020; DOI: 10.1038/s41423-020-0374-2.
    CrossrefPubMedGoogle Scholar
  • 16 Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect 2020; 22 (02) 74-79
    CrossrefPubMedGoogle Scholar
  • 17 de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host factors in Coronavirus replication. Curr Top Microbiol Immunol 2018; 419: 1-42
    PubMedGoogle Scholar
  • 18 Sawicki SG, Sawicki DL. Coronavirus transcription: a perspective. In: Current Topics in Microbiology and Immunology. Berlin Heidelberg: Springer; 2005: 31-55
    Google Scholar
  • 19 Hussain S, Pan J, Chen Y. et al. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J Virol 2005; 79 (09) 5288-5295
    CrossrefPubMedGoogle Scholar
  • 20 Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pd. Accessed May 17, 2020
  • 21 Guan W-J, Ni Z-Y, Hu Y. et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
    CrossrefPubMedGoogle Scholar
  • 22 Huang L, Shi Y, Gong B. et al. Blood single cell immune profiling reveals the interferon-mapk pathway mediated adaptive immune response for COVID-19. Infectious Diseases (Except HIV AIDS (Auckl) 2020; DOI: 10.1101/2020.03.15.20033472.
    CrossrefPubMedGoogle Scholar
  • 23 Lee N, Hui D, Wu A. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348 (20) 1986-1994
    CrossrefPubMedGoogle Scholar
  • 24 Jiang G, Ren X, Liu Y. et al. Application and optimization of RT-PCR in diagnosis of SARS-CoV-2 infection. medRxiv 2020; DOI: 10.1101/2020.02.25.20027755.
    CrossrefPubMedGoogle Scholar
  • 25 Ai T, Yang Z, Hou H. et al. Correlation of chest CT and RT-PCR testing in Coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020; DOI: https://doi.org/10.1148/radiol.2020200642.
    CrossrefPubMedGoogle Scholar
  • 26 ThermoFisher Scientific. Random Primers & Oligo(dT)s - IN. Available at: https://www.thermofisher.com/in/en/home/life-science/oligonucleotides-primers- probes-genes/other-dna-primers-oligos.html. Accessed May 17, 2020
  • 27 Yang Q, Liu Q, Xu H, Lu H, Liu S, Li H. Imaging of coronavirus disease 2019: A Chinese expert consensus statement. Eur J Radiol 2020; 127: 109008
    CrossrefPubMedGoogle Scholar
  • 28 Qin C, Zhou L, Hu Z. et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; DOI: 10.1093/cid/ciaa248.
    CrossrefPubMedGoogle Scholar
  • 29 Richardson S, Hirsch JS, Narasimhan M. et al. and the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020; DOI: 10.1001/jama.2020.6775.
    CrossrefPubMedGoogle Scholar
  • 30 CDC. National Diabetes Statistics Report | Data & Statistics | Diabetes | CDC. Available at: https://www.cdc.gov/diabetes/data/statistics/statistics-report.html. Accessed May 17, 2020
  • 31 Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; DOI: 10.1001/jama.2020.4683.
    CrossrefPubMedGoogle Scholar
  • 32 Ferguson N, Laydon D, Nedjati Gilani G, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. Available at: https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf. Accessed June 22, 2020
  • 33 CDC COVID-19 Response Team. Severe outcomes among patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. Morb Mortal Wkly Rep 2020; 69 (12) 343-346
    CrossrefPubMedGoogle Scholar
  • 34 Arentz M, Yim E, Klaff L. et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020; 323 (16) 1612
    CrossrefPubMedGoogle Scholar
  • 35 INTENSIVE. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) | INTENSIVE Review. INTENSIVE. Available at: https://intensiveblog.com/report-of-the-who-china-joint-mission-on- coronavirus-disease-2019-covid-19/. Accessed May 11, 2020
  • 36 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229) 1054-1062
    CrossrefPubMedGoogle Scholar
  • 37 Maddaloni E, Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev 2020; DOI: 10.1002/dmrr.3321.
    CrossrefPubMedGoogle Scholar
  • 38 Knapp S. Diabetes and infection: is there a link?–A mini-review. Gerontology 2013; 59 (02) 99-104
    CrossrefPubMedGoogle Scholar
  • 39 Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol 2018; 34 (05) 575-584
    CrossrefPubMedGoogle Scholar
  • 40 Lingeswaran M, Goyal T, Ghosh R. et al. Inflammation, immunity and immunogenetics in COVID-19: A Narrative Review. Ind J Clin Biochem 2020; DOI: 10.1007/s12291-020-00897-3.
    CrossrefPubMedGoogle Scholar
  • 41 Huang Y-T, Lee Y-C, Hsiao C-J. Hospitalization for ambulatory-care-sensitive conditions in Taiwan following the SARS outbreak: a population-based interrupted time series study. J Formos Med Assoc 2009; 108 (05) 386-394
    CrossrefPubMedGoogle Scholar
  • 42 Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology 2003; 8 (Suppl) S9-S14
    CrossrefPubMedGoogle Scholar
  • 43 Morra ME, Van Thanh L, Kamel MG. et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis. Rev Med Virol 2018; 28 (03) e1977
    CrossrefPubMedGoogle Scholar
  • 44 Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020
  • 45 Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26 (02) 510-513
    CrossrefPubMedGoogle Scholar
  • 46 Muller LMAJ, Gorter KJ, Hak E. et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41 (03) 281-288
    CrossrefPubMedGoogle Scholar
  • 47 Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341 (25) 1906-1912
    CrossrefPubMedGoogle Scholar
  • 48 Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol 2009; 302 (02) 193-202
    CrossrefPubMedGoogle Scholar
  • 49 Bornstein SR, Rubino F, Khunti K. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020; 8 (06) 546-550
    CrossrefPubMedGoogle Scholar
  • 50 Cure E, Cumhur Cure M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. Diabetes Metab Syndr 2020; 14 (04) 349-350
    CrossrefPubMedGoogle Scholar
  • 51 Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci 2017; 18 (03) 563
    Google Scholar
  • 52 Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010; 47 (03) 193-199
    CrossrefPubMedGoogle Scholar
  • 53 Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323 (11) 1061
    CrossrefPubMedGoogle Scholar
  • 54 Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41 (02) 145-151
    PubMedGoogle Scholar
  • 55 Kreutz R, Algharably EA, Azizi M. et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res 2020; DOI: 10.1093/cvr/cvaa097.
    CrossrefPubMedGoogle Scholar
  • 56 Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020; 382 (17) 1653-1659
    CrossrefPubMedGoogle Scholar
  • 57 Ferrario CM, Jessup J, Chappell MC. et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111 (20) 2605-2610
    CrossrefPubMedGoogle Scholar
  • 58 Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 2020; 75 (06) 1382-1385
    CrossrefPubMedGoogle Scholar
  • 59 Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol 2019; 19 (08) 517-532
    CrossrefPubMedGoogle Scholar
  • 60 Siedlinski M, Jozefczuk E, Xu X. et al. White blood cells and blood pressure: a Mendelian randomization study. Circulation 2020; 141 (16) 1307-1317
    CrossrefPubMedGoogle Scholar
  • 61 Xu Z, Shi L, Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8 (04) 420-422
    CrossrefPubMedGoogle Scholar
  • 62 Wu Y, Xu X, Yang L, Liu C, Yang C. Nervous system damage after COVID-19 infection: Presence or absence?. Brain Behav Immun 2020; DOI: 10.1016/j.bbi.2020.04.043.
    CrossrefPubMedGoogle Scholar
  • 63 Desforges M, Le Coupanec A, Dubeau P. et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?. Viruses 2019; 12 (01) E14
    CrossrefPubMedGoogle Scholar
  • 64 Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the cns: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020; 11 (07) 995-998
    CrossrefPubMedGoogle Scholar
  • 65 Wu Y, Xu X, Chen Z. et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020; DOI: 10.1016/j.bbi.2020.03.031.
    CrossrefPubMedGoogle Scholar
  • 66 Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Front Cell Neurosci 2018; 12: 386
    CrossrefPubMedGoogle Scholar
  • 67 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229) 1033-1034
    CrossrefPubMedGoogle Scholar
  • 68 Mao L, Wang M, Chen S. et al. Neurological manifestations of hospitalized patients with covid-19 in wuhan, china: a retrospective case series study. Infectious Diseases (Except HIV AIDS (Auckl) 2020; DOI: 10.1101/2020.02.22.20026500.
    CrossrefPubMedGoogle Scholar
  • 69 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
    CrossrefPubMedGoogle Scholar
  • 70 Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis 2006; 17 (06) 445-451
    CrossrefPubMedGoogle Scholar
  • 71 Bikdeli B, Madhavan MV, Jimenez D. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020; DOI: 10.1016/j.jacc.2020.04.031.
    CrossrefPubMedGoogle Scholar
  • 72 Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol 2020; 153 (06) 725-733
    CrossrefPubMedGoogle Scholar
  • 73 Han H, Yang L, Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; DOI: 10.1515/cclm-2020-0188.
    CrossrefPubMedGoogle Scholar
  • 74 Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020; 506: 145-148
    CrossrefPubMedGoogle Scholar
  • 75 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18 (05) 1094-1099
    CrossrefPubMedGoogle Scholar
  • 76 Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost 2020; 120 (05) 876-878
    Article in Thieme ConnectPubMedGoogle Scholar
  • 77 Leonard-Lorant I, Delabranche X, Severac F. et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology 2020; DOI: 10.1148/radiol.2020201561.
    CrossrefPubMedGoogle Scholar
  • 78 Wada H, Thachil J, Di Nisio M. et al. The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; DOI: 10.1111/jth.12155.
    CrossrefPubMedGoogle Scholar
  • 79 Barrett CD, Moore HB, Yaffe MB, Moore EE. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment. J Thromb Haemost 2020; DOI: 10.1111/jth.14860.
    CrossrefPubMedGoogle Scholar
  • 80 Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9 (01) 727-732
    CrossrefPubMedGoogle Scholar
  • 81 Wang J, Hajizadeh N, Moore EE. et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost 2020; DOI: 10.1111/jth.14828.
    CrossrefPubMedGoogle Scholar
  • 82 Arleevskaya MI, Shafigullina AZ, Filina YV, Lemerle J, Renaudineau Y. Associations between viral infection history symptoms, granulocyte reactive oxygen species activity, and active rheumatoid arthritis disease in untreated women at onset: results from a longitudinal cohort study of Tatarstan women. Front Immunol 2017; 8: 1725
    CrossrefPubMedGoogle Scholar
  • 83 Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013; 52 (01) 53-61
    CrossrefPubMedGoogle Scholar
  • 84 Galloway JB, Hyrich KL, Mercer LK. et al. BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50 (01) 124-131
    CrossrefPubMedGoogle Scholar
  • 85 Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46 (09) 2294-2300
    CrossrefPubMedGoogle Scholar
  • 86 Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007; 66 (03) 308-312
    CrossrefPubMedGoogle Scholar
  • 87 Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2018; 77 (06) 905-910
    PubMedGoogle Scholar
  • 88 Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents 2020; 55 (05) 105938
    CrossrefPubMedGoogle Scholar
  • 89 Maggini S, Pierre A, Calder PC. Immune Function and Micronutrient Requirements Change over the Life Course. Nutrients 2018; 10 (10) E1531
    CrossrefPubMedGoogle Scholar
  • 90 Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2013; 8 (06) e65835
    CrossrefPubMedGoogle Scholar
  • 91 Charan J, Goyal JP, Saxena D, Yadav P. Vitamin D for prevention of respiratory tract infections: a systematic review and meta-analysis. J Pharmacol Pharmacother 2012; 3 (04) 300-303
    CrossrefPubMedGoogle Scholar
  • 92 Teymoori-Rad M, Shokri F, Salimi V, Marashi SM. The interplay between vitamin D and viral infections. Rev Med Virol 2019; 29 (02) e2032
    CrossrefPubMedGoogle Scholar
  • 93 Grant WB, Lahore H, McDonnell SL, et al. Vitamin D supplementation could prevent and treat influenza, coronavirus, and pneumonia infections. Published online March 15, 2020. Doi: 10.20944/preprints202003.0235.v1
  • 94 Nair R, Maseeh A. Vitamin D: The “sunshine” vitamin. J Pharmacol Pharmacother 2012; 3 (02) 118-126
    PubMedGoogle Scholar
  • 95 Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80 (06) (Suppl) 1678S-1688S
    CrossrefPubMedGoogle Scholar
  • 96 van Driel ML, Beller EM, Thielemans E. et al. Oral vitamin C supplements to prevent and treat acute upper respiratory tract infections. Cochrane Acute Respiratory Infections Group, ed, Cochrane Database Syst Rev Published online March 19, 2019 DOI: 10.1002/14651858.CD013292.
    CrossrefGoogle Scholar
  • 97 Maggini S, Beveridge S, Suter M. A combination of high-dose vitamin C plus zinc for the common cold. J Int Med Res 2012; 40 (01) 28-42
    CrossrefGoogle Scholar
  • 98 Uyeki TM, Bernstein HH, Bradley JS. et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 2019; 68 (06) e1-e47
    CrossrefPubMedGoogle Scholar
  • 99 Liu J, Cao R, Xu M. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6 (01) 16
    CrossrefPubMedGoogle Scholar
  • 100 Syal K. COVID-19: Herd immunity and convalescent plasma transfer therapy. J Med Virol 2020; DOI: 10.1002/jmv.25870.
    CrossrefPubMedGoogle Scholar
  • 101 Cheng Y, Wong R, Soo YO. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24 (01) 44-46
    CrossrefPubMedGoogle Scholar